2019
Hippocampal Subfields in Acute and Remitted Depression—an Ultra-High Field Magnetic Resonance Imaging Study
Kraus C, Seiger R, Pfabigan D, Sladky R, Tik M, Paul K, Woletz M, Gryglewski G, Vanicek T, Komorowski A, Kasper S, Lamm C, Windischberger C, Lanzenberger R. Hippocampal Subfields in Acute and Remitted Depression—an Ultra-High Field Magnetic Resonance Imaging Study. The International Journal Of Neuropsychopharmacology 2019, 22: 513-522. PMID: 31175352, PMCID: PMC6672627, DOI: 10.1093/ijnp/pyz030.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAffectAntidepressive Agents, Second-GenerationAustriaCitalopramDepressive Disorder, MajorDrug SubstitutionFemaleHippocampusHumansMagnetic Resonance ImagingMaleMiddle AgedPredictive Value of TestsRemission InductionSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsTreatment OutcomeVenlafaxine HydrochlorideYoung AdultConceptsMajor depressive disorderDepressive disorderHippocampal subfieldsSubfield volumesAntidepressant treatmentHealthy controlsHippocampal-amygdaloid transition areaMajor depressive disorder patientsOpen-label studyMagnetic resonance imaging studyDepressive disorder patientsHippocampal formation volumeStructural magnetic resonance imagingHippocampal volume changesLower baseline volumesTreatment-related changesResonance imaging studyMagnetic resonance imagingMeasurement time pointsSerotonergic antidepressantsWeeks treatmentAcute patientsRight subiculumUnmedicated patientsBaseline volumeThe effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography
Baldinger-Melich P, Gryglewski G, Philippe C, James GM, Vraka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz GS, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimulation 2019, 12: 714-723. PMID: 30635228, DOI: 10.1016/j.brs.2018.12.976.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyTRD patientsMAO-A levelsHealthy subjectsPositron emission tomographyTest-retest variabilityMechanism of actionEffective antidepressant treatment strategiesSex-matched healthy subjectsEmission tomographyAntidepressant treatment strategiesMonoamine oxidaseTreatment-resistant depressionTreatment-resistant patientsSerotonin 1A receptorUnmedicated depressed patientsCerebral monoamine oxidasesCerebral MAOAntidepressant pharmacotherapyECT sessionsAntidepressant treatmentDepressed patientsMajor depressionSerotonergic systemTreatment strategies
2017
Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression
James GM, Baldinger-Melich P, Philippe C, Kranz GS, Vanicek T, Hahn A, Gryglewski G, Hienert M, Spies M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R. Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression. Frontiers In Human Neuroscience 2017, 11: 48. PMID: 28220069, PMCID: PMC5292566, DOI: 10.3389/fnhum.2017.00048.Peer-Reviewed Original ResearchSelective serotonin reuptake inhibitorsPositron emission tomographySerotonin reuptake inhibitorsMajor depressive disorderHealthy controlsReuptake inhibitorsSerotonergic neurotransmissionBrain regionsState functional magnetic resonance imaging studySerotonin transporterMagnetic resonance imaging studyReuptake of serotoninSerotonin transporter availabilityResonance imaging studyFunctional magnetic resonance imaging studyAnterior cingulate cortexSSRI doseAntidepressant effectsAntidepressant treatmentClinical outcomesSSRI administrationMDD patientsDepressive disorderMajor depressionMDD pathophysiology